New Pill Shows Promise for Alzheimer’s Patients
Researchers have found that an experimental pill may help slow down memory loss and brain shrinkage in certain Alzheimer’s patients. This new medication, named ALZ-801, targets individuals in the early stages of Alzheimer’s, particularly those who carry the APOE4 gene, known to significantly increase the risk of developing the disease.
The study, carried out by Alzheon, Inc., a biotech company from Massachusetts, involved 325 participants aged between 50 and 80 who were experiencing mild cognitive impairment (MCI) or mild dementia. These participants were given either the ALZ-801 pill or a placebo for a duration of 18 months.
While the results showed a slight reduction in memory decline for the overall group, this difference wasn’t statistically significant. However, those with mild cognitive impairment experienced a notable 50% slowdown in memory decline, and nearly all daily cognitive decline was halted.
Dr. Christopher Weber from the Alzheimer’s Association highlighted that individuals diagnosed with MCI still retain many daily living skills despite experiencing cognitive challenges like memory and language issues.
In addition to slowing cognitive decline, those taking the ALZ-801 displayed slower brain shrinkage, particularly in the hippocampus, which is essential for memory. This reduction in brain atrophy was approximately 18% less compared to those receiving a placebo.
Published findings in the journal “Drugs” indicated manageable side effects primarily including nausea and appetite loss. Unlike existing Alzheimer’s treatments which require IV infusions, ALZ-801 could serve as a convenient oral option for caregivers and patients alike.
Benefits of ALZ-801 include not showing the brain swelling and bleeding side effects linked to current monoclonal antibody drugs that aim to break down amyloid plaques in the brain. This aspect gives hope that ALZ-801 might be safer for patients at higher risk of side effects.
Dr. Marc Siegel, a senior medical analyst, emphasized that the potential for this drug lies in its preventative nature, as it aims to stop amyloid plaques from forming in the first place.
Despite the promising results, researchers noted some limitations, such as the study’s focus on only APOE4 carriers and a relatively short trial period. More research is needed to confirm these outcomes and to explore how this drug may work in conjunction with other Alzheimer’s treatments.
The findings were backed by funding from Alzheon, Inc., with additional support from a grant from the U.S. National Institute on Aging.
Overall, the research indicates that ALZ-801 could be a significant addition to the available treatments for Alzheimer’s disease, with further studies needed to validate these early encouraging results.
